Zenas BioPharma (ZBIO) Current Assets (2023 - 2026)
Zenas BioPharma (ZBIO) posted quarterly Current Assets of $730.2 million for Q1 2026, up 129.75% year-over-year from $317.8 million in Q1 2025, and up 107.92% quarter-over-quarter from $351.2 million in Q4 2025.
Zenas BioPharma (ZBIO) Current Assets (2023 - 2026) Analysis & Trends
Zenas BioPharma's Current Assets history runs 4 years deep, the most recent figure standing at $730.2 million for Q1 2026.
- In Q1 2026, Current Assets rose 129.75% year-over-year to $730.2 million; the TTM figure through Mar 2026 stood at $730.2 million (up 129.75% YoY), while the FY2025 annual figure was $351.2 million, down 1.34% from the prior year.
- Current Assets for Q1 2026 stood at $730.2 million, up from $351.2 million in the prior quarter.
- The five-year high for Current Assets was $730.2 million in Q1 2026, with the low at $59.8 million in Q4 2023.
- The 4-year median for Current Assets is $334.5 million (2025), against an average of $348.0 million.
- The sharpest annual moves came in 2024 and 2025: Current Assets soared 495.15% in 2024, then decreased 24.67% in 2025.
- Zenas BioPharma's Current Assets stood at $59.8 million in 2023, then jumped by 495.15% to $355.9 million in 2024, then retreated by 1.34% to $351.2 million in 2025, then soared by 107.92% to $730.2 million in 2026.
- Business Quant data shows ZBIO's Current Assets at $730.2 million in Q1 2026, $351.2 million in Q4 2025, and $296.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Zenas BioPharma | 1.87 Bn | 748.44 Mn | - | 653.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 653.79 Mn |
| Mar 31, 2026 | 730.16 Mn |
| Dec 31, 2025 | 351.17 Mn |
| Sep 30, 2025 | 296.64 Mn |
| Jun 30, 2025 | 278.60 Mn |
| Mar 31, 2025 | 317.81 Mn |
| Dec 31, 2024 | 355.92 Mn |
| Sep 30, 2024 | 393.78 Mn |
| Dec 31, 2023 | 59.80 Mn |